What do biomarkers tell us about the pathogenesis of ankylosing spondylitis?
Biomarkers may provide information that promotes understanding of prognosis, disease activity, and pathogenesis in ankylosing spondylitis. Biomarkers reflecting disease activity (metallo-proteinase-3) and inflammatory lesions on magnetic resonance imaging predict new bone formation and are ameliorated by anti-tumor necrosis factor therapy, yet this treatment may not prevent new bone formation. Moreover, elevated levels of biomarkers reflecting tissue repair (bone-specific alkaline phosphatase) post-treatment together with magnetic resonance imaging indicates such treatment may even promote repair through new bone formation. Tumor necrosis factor regulation of Dickkopf-1 may constitute a molecular brake that controls osteoblastogenesis through wingless and bone morphogenetic proteins in an established inflammatory lesion in ankylosing spondylitis.
Maksymowych
Walter P
WP
D000068879:Adalimumab; D000469:Alkaline Phosphatase / Q000097:blood; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis*; D006801:Humans; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D013167:Spondylitis, Ankylosing / Q000378:metabolism* / Q000473:pathology* / Q000503:physiopathology*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015415:Biomarkers; D042461:Vascular Endothelial Growth Factor A; D000469:Alkaline Phosphatase; D019278:Matrix Metalloproteinase 3; D000068879:Adalimumab